PSI-938 is an oral guanosine nucleotide analog polymerase inhibitor of HCV.
Earlier in Nuclear study , PSI-938 showed potent antiviral activity and was generally safe and well tolerated, both as monotherapy and in conjunction with the company’s lead nucleotide analog, PSI-7977.
Currently, Pharmasset intends to start Quantum combination trial with PSI-938 and PSI-7977 in the third quarter of 2011.